The endocannabinoid with a split personality. Virodhamine is both agonist and antagonist at the cannabinoid CB1 receptor — full agonist at CB2 — an endogenous ligand that broke the family's tidy rules.
Virodhamine — arachidonic acid esterified with ethanolamine in the reverse orientation of anandamide (the name is anandamide reversed) — was identified in 2002 among endogenous cannabinoids. Brain concentrations rival anandamide in regions mapped by lipidomics's in some regions, suggesting a standing endogenous tone rather than pure on-demand bursts. FAAH-class enzymes clear it.
Receptor Actions
CB1 partial antagonism in vivo — an endogenous counterweight to anandamide and 2-AG at the same receptor.
Full CB2 agonism — the immune-arm endocannabinoid profile.
Its mixed pharmacology showed the endocannabinoid family is not simply two agonists and a receptor.
Physiological Role
Contributes to baseline endocannabinoid tone measured across brain regions in the system's balance sheet.
Vascular and immune signaling via CB2 in peripheral tissues.
Its antagonism-at-CB1 profile in the system implies a role in limiting cannabinoid overshoot.
Interactions
Structural mirror of anandamide — one ester bond reversed, pharmacology inverted.
Coexists with 2-AG as the abundant agonist it may temper.
FAAH clearance ties it to the same metabolism as anandamide.
Clinical Relevance
A reminder that receptor ligands span agonist-to-antagonist spectra — endogenous inverse agents exist.
CB2-selectivity makes its profile interesting for anti-inflammatory drug design.
Human in-vivo roles remain mapped only in outline — a research frontier entry in endocannabinoid pharmacology.
Virodhamine inverted the structure-activity expectation and expanded the endocannabinoid lexicon.
Its discovery came from lipidomic screening — mass spectrometry finding what bioassays had missed.
Concentration estimates in hippocampus compete with anandamide's — the tone is real, the function mapped in outline.
Mixed-ligand pharmacology is now expected at cannabinoid receptors — virodhamine is the endogenous proof, joined by 2-AG and NADA dynamics.